arrow
J

John F. DiPersio

washington university in st louis
H指数:126
被引数:9.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

CRISPR−Cas9介导CD33基因敲除的异基因造血细胞移植联合吉姆单抗奥佐米星维持治疗急性髓系白血病:一项1/2期临床试验

2026-05-120
OAAI
BACH2 regulates T cell lineage state to enhance CAR T cell function

BACH2调节T细胞谱系状态以增强CAR T细胞功能

2026-01-160
PRE
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

单细胞图谱表征与多发性骨髓瘤结局相关的骨髓免疫微环境失调

2026-01-090
OAAI
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce GI Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

一项评估Uproleselan抑制E-选择素以减少多发性骨髓瘤自体造血细胞移植期间胃肠道毒性的II期随机、双盲、安慰剂对照试验

2025-11-090
PRE
Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis

新诊断多发性骨髓瘤中lncRNA表达的研究揭示了一个LINC01432-CELF2轴作为凋亡抑制剂

2025-10-060
OA
NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma

NKTR-255可增强CD19 CAR-T在复发/难治性大B细胞淋巴瘤患者中的完全缓解率。

2025-08-110
OAAI
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

I 期/II 期临床试验:评估抗CD7 异基因 WU-CART-007 在复发/难治性 T 细胞恶性肿瘤患者中的疗效

Blood
IF23.1
2025-06-020
PRE
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial

使用现场制备的CAR T细胞治疗非霍奇金淋巴瘤:一项双中心、1期临床试验

2025-03-010
OAAI
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma

I期研究:NT-I7(一种长效白介素-7)在标准放疗和替莫唑胺治疗高级别胶质瘤后严重治疗相关性淋巴细胞减少中的应用

2025-01-011
OA
NT-I7, A LONG-ACTING INTERLEUKIN-7, PROMOTES ACTIVATION, CYTOTOXIC FUNCTION, AND SELECTIVE CLONOTYPE EXPANSION OF CD8+T CELLS IN PATIENTS WITH HIGH GRADE GLIOMAS
2024-11-110
PRE
Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study

Motixafortide(CXCR4抑制)单独及联合Natalizumab(VLA-4抑制)作为动员造血干细胞用于镰状细胞病基因治疗的新型方案:一项首次人体、原理验证的安全性及可行性研究

BLOOD
IF23.1
2024-11-050
PRE
Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

白血病相关突变(LAMs)在诱导治疗后清除与中危急性髓系白血病的不良预后相关:一项多中心、前瞻性II期试验的 interim 结果

BLOOD
IF23.1
2024-11-050
PRE
RNA Modifications on Long Non-Coding RNAs in Multiple Myeloma

多发性骨髓瘤中长链非编码RNA的RNA修饰

BLOOD
IF23.1
2024-11-050
PRE